3i Fund provides Cerenome with up to $20m senior secured facility
The Houston CNS oncology company will use the royalty-based financing to scale its CNSide cerebrospinal fluid assay and said cash runway now extends into 2028.
1 min read11 Sept 2026Individual financings — raised, refinanced, extended — and the terms behind them.
The Houston CNS oncology company will use the royalty-based financing to scale its CNSide cerebrospinal fluid assay and said cash runway now extends into 2028.
1 min read11 Sept 2026The facility refinances the construction loan on the Washington e-SAF plant and will fund expansion including additional hydrogen capacity.
1 min read11 Sept 2026Proceeds will advance clinical development of ETH47 for asthma and COPD and related respiratory mRNA programmes, including mucosal influenza vaccine candidates.
1 min read10 Sept 2026The California power electronics company also appointed former Tesla chief financial officer Zach Kirkhorn to its board as it scales Factory One production.
1 min read10 Sept 2026Proceeds will support commercial expansion of the NEUROMARK System and sales and marketing investment after a €62.5m Series C earlier this year.
1 min read9 Sept 2026The Mexico City lender will use the capital to accelerate product innovation and expand across Mexico, the United States and other markets.
1 min read9 Sept 2026Proceeds will fund higher marketing spend on proven cohorts across the studio’s consumer apps and AI products.
1 min read8 Sept 2026Companies House lists Gilion Credit I AB as chargeholder on a filing created and delivered on 10 June 2026.
1 min read8 Sept 2026The facility carries a 10% coupon, amortises from December and includes an accordion for up to $10m more subject to conditions and additional warrants.
2 min read7 Sept 2026Intellia drew $75 million at closing under the five-year facility, which matures on 4 September 2031.
2 min read7 Sept 2026